Monthly Notifiable Disease Surveillance Report - Nov 2017

Saturday 20th January 2018


Key notifiable disease trends

Cryptosporidiosis: 119 cases of cryptosporidiosis (118 confirmed and 1 under investigation) were notified in November 2017 compared to 95 cases notified in November 2016. The 12-month rate for the period ending 30 November (25.6 cases per 100,000 population) was slightly higher than for the same period in the previous year (22.3 per 100,000). Cases ranged in age from 9 months to 95 years, with the highest numbers of cases in the 1–4 years (31 cases) and 20–29 years (23 cases) age groups. Among the cases for which risk factor information was recorded, 54.1% (33/61) had contact with farm animals, 41.5% (22/53) consumed untreated water, 40.0% (24/60) had attended school, preschool or childcare, 26.8% (15/56) had contact with faecal matter or vomit, 21.6% (11/51) had contact with sick animals and 20.4 (11/54) had consumed food from a food premises) during the incubation period. Three finalised Cryptosporidium outbreak (8 cases) were created in November.

Dengue Fever: 25 cases of dengue fever (24 confirmed and 1 under investigation) were notified in November 2017 compared to 13 cases notified in November 2016. All cases had been overseas during the incubation period. The countries/regions visited included Samoa (16 cases), India (5 cases), American Samoa, China, French Polynesia, Malaysia, North Africa, Singapore, and Sri Lanka (1 case each). Three cases reported overseas travel to more than one country.

Hepatitis A: 10 cases of hepatitis A (9 confirmed and 1 under investigation) were notified in November 2017 compared to eight cases notified in October 2017 and three cases notified in November 2016. The cases were reported from Waikato, MidCentral (3 cases each), Northland (2 cases), Auckland and Counties Manukau (1 case each) DHBs. Nine cases were laboratory confirmed. Ethnicity was recorded for 80.0% (8/10) cases, and were reported as being in Māori (5 cases) and European or Other (3 cases). The cases ranged in age from 3 to 81 years, with the highest number of cases in the 1–4 years and 30–39 years age groups (2 cases each). Risk factor information was recorded for six cases: eating recreationally collected shellfish (3 cases), attending a pre-school or childcare (2 cases) and overseas travel (1 case).

Leptospirosis: 21 cases of leptospirosis (14 confirmed, 3 probable, and 4 under investigation) were notified in November 2017 compared to 12 cases notified in November 2016. The highest number of cases was reported in the 50–59 years (6 cases) and 20–29 years (5 cases) age groups. Occupation was recorded for 85.7% (18/21) of cases. Of these, 15 were engaged in occupation previously identified as high risk exposure to Leptospira species: farmers or farm workers (14 cases) and meat workers (1 case). Two additional cases reported exposure through contact with animal/manure. Four cases did not have any risk factor information recorded. One interim Leptospira outbreak (case numbers yet to be determined) was created in November.

Meningococcal disease: 11 cases of meningococcal disease (9 confirmed and 2 under investigation) were notified in November 2017 compared to 12 cases notified in November 2016. The highest number of cases were reported from Waitemata and Bay of Plenty (2 cases each) DHBs. The cases were in the less than one year (3 cases), 1–4 years, 70 years and over (2 cases each), 5–9 years, 15–19 years, 50–59 years, and 60–69 (1 case each) age groups. Ten cases were hospitalised and no deaths were reported. Ten cases were laboratory confirmed and the group was determined for nine of these cases: group B (5 cases, including 2 NZ B:P1.7-2,4), group W (2 cases), group C (1 case) and group Y (1 case).

Mumps: 261 cases of mumps (134 confirmed, 48 probable and 79 under investigation) were notified in November 2017 compared with one case notified in November 2016 (Figure 1). The 12-month rate for the period ending 30 November was 25.5 cases per 100,000 population. The highest numbers of cases were reported from Counties Manukau (91 cases), Auckland (74 cases), and Waitemata (41 cases) DHBs. The highest numbers of cases were in the 20–29 years (95 cases) and 15–19 years (54 cases) age groups. Ninety-one cases were recorded as being vaccinated against mumps, of which 70 cases had received two doses of the vaccine and 19 cases had received just one dose. Two further cases had been vaccinated, but no dose information was availableand 49 cases were recorded as non-vaccinated. Vaccination status was unknown for 82 cases One interim mumps outbreak (cases number yet to be determined) was created in November.

Pertussis: 436 cases of pertussis (211 confirmed, 146 probable, 7 suspected, and 72 under investigation) were notified in November 2017 compared to 107 cases in November 2016 (Figure 2). The 12-month rate for the period ending 30 November (38.1 cases per 100,000) was higher than for the same period in the previous year (22.6 per 100,000). Twenty cases were hospitalised and no deaths were reported. Forty-nine percent (215/436) of cases were laboratory-confirmed (33 by culture, 147 by PCR, and 35 by culture and PCR). The highest number of cases was reported from Nelson Marlborough DHB (86 cases), followed by Waikato (47 cases), Auckland (45 cases) and Waitemata (40 cases) DHBs. Cases ranged in age from 1 month to 92 years, with 11.7% (51/436) under five years of age (including 19 cases aged less than 1 year). The highest numbers of cases were in the 10–14 years (69 cases), 5–9 years (67 cases), 15–19 years (51 cases) and 40–49 years (50 cases) age groups.

Shigellosis: 26 confirmed cases of shigellosis were notified in November 2017 compared with 18 cases notified in November 2016. The 12-month rate for the period ending 30 November (5.2 cases per 100,000 population) was higher than at the same time in the previous year (3.3 per 100,000). The highest number of cases was reported from Auckland (5 cases) DHB. The serotype involved was recorded for 73.1% (19/26) of cases: S. sonnei biotype g (5 cases), S. flexneri 1b (4 cases), S. flexneri 2a, S. sonnei biotype a (3 cases each), S. flexneri 3b (2 cases), S. boydii 4 and S. flexneri 2b (1 case each). Information on overseas travel during the incubation period was recorded for 65.4% (17/26) of cases, of which 70.6% (12/17) of cases recorded overseas travel during this period. Countries visited included: India, Indonesia, Tonga, Vanuatu (2 cases each), Cambodia, Croatia, Fiji, Kiribati, Samoa and Vietnam (1 case each). Two cases reported overseas travel to more than one country.

VTEC/STEC infection: 48 cases of VTEC/STEC infection (39 confirmed and 9 under investigation) were notified in November 2017 compared to 32 cases notified in November 2016. The 12-month rate for the period ending 31 November 2017 (11.5 cases per 100,000 population) was higher than at the same time period in the previous year (9.3 cases per 100,000 population). The highest numbers of cases were reported from Southern (18 cases) and Waitemata (9 cases) DHBs. Cases ranged in age from 1 month to 85 years, with the highest number of cases in the 1–4 years (9 cases) age group. Nine cases were hospitalised. Twenty cases have been confirmed by the Enteric Reference Laboratory as being infected with VTEC/STEC, and of these the serotype was identified as Escherichia coli O157:H7 (7 cases) and non-O157 (13 cases). Of the cases for which risk factor information was recorded, 70.0% (21/30) had contact with animals, 29.6% (8/27) had contact with children in nappies, 22.6% (7/31) had contact with a person with similar symptoms and 18.5% (5/27) had recreational contact with water during the incubation period. One final (2 cases) and one interim VTEC/STEC infection outbreak (case numbers yet to be determined) was created in November.

Note: Click on the document links below to open. These documents are in PDF format. You will need to download the free Adobe Acrobat Reader to view them.

Report:

Monthly Notifiable Disease Surveillance Report - Nov 2017

Tables:

Monthly National Totals - November 2017

Monthly DHB Totals - November 2017

Monthly Rolling Totals - November 2017

 

DOWNLOADS

Monthly Notifiable Disease Surveillance Report - Nov 2017

Tables:

Monthly National Totals - November 2017

Monthly DHB Totals - November 2017

Monthly Rolling Totals - November 2017

Ph: +64 4 914 0700
Fax: +64 4 914 0770
Email: survqueries@esr.cri.nz